Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy
- Urruticoechea, A.
- Rizwanullah, M.
- Im, S.-A.
- Sánchez Ruiz, A.C.
- Láng, I.
- Tomasello, G.
- Douthwaite, H.
- Crnjevic, T.B.
- Heeson, S.
- Eng-Wong, J.
- Muñoz, M.
ISSN: 1527-7755, 0732-183X
Year of publication: 2017
Volume: 35
Issue: 26
Pages: 3030-3038
Type: Conference paper